Neuropathic Pain
- What Neuropathic Pain Is
- Peripheral vs. Central Sensitization
- Common Causes and Conditions
- How Neuropathic Pain Feels: Symptoms and Descriptors
- DN4 Diagnostic Tool
- Diagnosing the Underlying Cause
- Gabapentinoids: Mechanism and Efficacy
- Serotonin-Norepinephrine Reuptake Inhibitor Treatment: Duloxetine
- Topical Treatments
- Alpha-Lipoic Acid and Evidence
- Other Treatment Options
- Complications
- Key Research Papers
- Connections
What Neuropathic Pain Is
Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system — the network of nerves responsible for sensing and transmitting information about pain, temperature, touch, and position. Unlike nociceptive pain (the normal protective pain signal from injured tissue — a stubbed toe, a burn), neuropathic pain arises from abnormal firing of damaged nerves themselves. The pain persists even when no tissue damage is occurring, and standard pain relievers often provide little relief. It affects an estimated 7–10% of the general population. Quality of life impacts are profound: sleep disruption, depression, anxiety, and reduced ability to work and socialize are common.
Peripheral vs. Central Sensitization
Understanding the difference helps explain why neuropathic pain is so hard to treat:
- Peripheral sensitization: Damaged peripheral nerves (outside the brain and spinal cord) develop ectopic firing — they spontaneously generate pain signals without a stimulus. Damaged nerves may also sprout abnormally, acquire new sodium channels, and become hypersensitive to normally harmless stimuli (such as light touch causing pain — allodynia).
- Central sensitization: Prolonged or intense peripheral nociceptive input changes the spinal cord and brain. N-methyl-D-aspartate (NMDA) receptors in the dorsal horn become hyperexcitable ("wind-up"); inhibitory pathways (serotonin-norepinephrine descending pain modulation) become less effective; the brain's pain matrix is reorganized to amplify signals. Central sensitization means that even after peripheral nerve healing, the central nervous system continues generating pain. It also explains why treatments that work on peripheral nerves alone often fail in long-standing neuropathic pain.
Common Causes and Conditions
- Diabetic peripheral neuropathy: Most common cause in the US; ~50% of long-term diabetics develop it; stocking-glove distribution (feet/hands)
- Postherpetic neuralgia (PHN): Persistent pain after herpes zoster (shingles); risk increases sharply with age
- Trigeminal neuralgia: Severe brief electric-shock pain in the face; most common cause is blood vessel compression of the trigeminal nerve
- Chemotherapy-induced peripheral neuropathy (CIPN): Taxanes, platinum compounds, vinca alkaloids, bortezomib
- Human immunodeficiency virus-associated neuropathy: Direct viral infection of neurons and immune-mediated damage
- Small fiber neuropathy (SFN): Affects unmyelinated C fibers and lightly myelinated Aδ fibers; often overlooked; skin biopsy for diagnosis
- Complex Regional Pain Syndrome (CRPS): Overlaps substantially with neuropathic pain
- Spinal cord injury: Central neuropathic pain above and below the injury level
- Phantom limb pain: Pain perceived in an amputated limb; related to cortical remapping
- Post-surgical neuropathic pain: Thoracotomy, mastectomy, hernia repair (inguinal nerve injury)
- Radiculopathy: Nerve root compression from disc herniation (sciatica is the most common example)
- Multiple sclerosis: Central neuropathic pain from demyelinating lesions
- Idiopathic small fiber neuropathy: No identifiable cause; possibly immune-mediated in many cases
How Neuropathic Pain Feels: Symptoms and Descriptors
Neuropathic pain has a distinctive character that distinguishes it from musculoskeletal pain. Patients describe:
- Burning: The most characteristic description — a continuous burning or heat sensation, often in the skin surface
- Electric shocks: Brief, lancinating shooting pain like an electric jolt
- Tingling and pins-and-needles (paresthesia): Usually present even at rest
- Numbness: Paradoxically, areas can be both numb AND painful simultaneously
- Allodynia: Pain from stimuli that should not hurt — light touch of clothing, a breeze, water from the shower
- Hyperalgesia: Exaggerated pain response to stimuli that are mildly painful
- Wind-up: Repeated stimulation causes escalating pain (due to central sensitization)
- Spontaneous pain at rest: Pain is present without any stimulus at all
- Worse at night: Very commonly disturbs sleep
DN4 Diagnostic Tool
The Douleur Neuropathique 4 (DN4) questionnaire is the most widely validated bedside tool for identifying neuropathic pain. It has a sensitivity of 82.9% and specificity of 89.9% for neuropathic pain vs. nociceptive pain. Score ≥4/10 indicates neuropathic pain.
Interview questions (patient reports):
- Does the pain have a burning quality?
- Is there a sensation of painful cold?
- Does the pain resemble electric shocks?
- Does pain feel like tingling?
- Does it feel like pins and needles?
- Does it feel like numbness?
Examination findings (clinician tests):
- Is the pain area hypoesthetic to touch?
- Is the pain area hypoesthetic to pinprick?
- Does brushing increase pain in the area?
- Does the pain area have autonomic signs?
Diagnosing the Underlying Cause
Diagnostic workup depends on clinical features and distribution. Standard evaluation includes:
- Detailed neurological examination
- Fasting glucose, hemoglobin A1c (HbA1c) (diabetes)
- B12 and folate (deficiency neuropathy)
- Thyroid-stimulating hormone (TSH) (hypothyroid neuropathy)
- Complete blood count (CBC) and erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP)
- Serum protein electrophoresis (SPEP) for paraproteinemia
- Nerve conduction studies (NCS) and electromyography (EMG) — evaluate large fiber function
- Skin punch biopsy for intraepidermal nerve fiber density — the gold standard for small fiber neuropathy diagnosis
- Magnetic resonance imaging (MRI) for radiculopathy or central causes
- Genetic testing if hereditary neuropathy suspected (Charcot-Marie-Tooth)
Gabapentinoids: Mechanism and Efficacy
Gabapentin and pregabalin are first-line agents for many neuropathic pain types. Despite the name, they do not work at gamma-aminobutyric acid (GABA) receptors. Their actual mechanism: they bind to the α2δ (alpha-2-delta) subunit of voltage-gated calcium channels on presynaptic nerve terminals in the dorsal horn of the spinal cord. This reduces calcium influx and therefore decreases neurotransmitter release (including substance P, glutamate, and calcitonin gene-related peptide, CGRP) — dampening central sensitization.
Efficacy: In the 2015 Neuropathic Pain Special Interest Group (NeuPSIG) meta-analysis of 229 studies, the combined number needed to treat (NNT) for 50% pain relief was 7.7 for pregabalin and 7.2 for gabapentin — meaning about 7 to 8 people are treated for one to gain that much relief. The 2025 update (313 trials) put the NNT for the class as a whole (alpha-2-delta ligands) at 8.9. Response is variable and cannot be predicted.
Dosing: Gabapentin starts at 100–300 mg at bedtime, increases slowly to 900–3600 mg/day in divided doses. Pregabalin (faster onset, more linear absorption) starts at 75 mg twice daily, increases to 150–300 mg twice daily.
Side effects: sedation, dizziness, weight gain, peripheral edema, cognitive dulling — often dose-limiting. New pharmacovigilance concerns about misuse/dependence (particularly gabapentin) in the UK and some US states.
Comparing the first-line drugs: The UK OPTION-DM trial (2022; 130 people with painful diabetic neuropathy) gave amitriptyline, duloxetine and pregabalin in turn, each topped up with a second drug after 6 weeks if pain was still above 3 out of 10. All three treatment pathways gave similar relief: average pain fell from 6.6 to 3.3 out of 10 by week 16. Pain fell a further 1.0 point on average in people given the combination, against 0.2 points in those who stayed on one drug. Side effects followed each drug: more dizziness with pregabalin first, nausea with duloxetine first, and dry mouth with amitriptyline first.
Serotonin-Norepinephrine Reuptake Inhibitor Treatment: Duloxetine
Serotonin-norepinephrine reuptake inhibitors (SNRIs) are a first-line option for diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain.
Mechanism: Inhibit reuptake of both serotonin and norepinephrine in the descending pain modulation pathways from the periaqueductal gray and brainstem to the dorsal horn — enhancing the body's own pain-suppression circuitry. Norepinephrine is the key mediator (this explains why drugs that act on norepinephrine relieve pain better than selective serotonin reuptake inhibitors, SSRIs).
Duloxetine: U.S. Food and Drug Administration-approved for diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Dose: 30 mg daily for 1 week then 60 mg daily. In the 2015 NeuPSIG meta-analysis the combined NNT for 50% pain relief was 6.4 for the SNRIs (mostly duloxetine trials); the 2025 update put the class at 7.4. Common side effects: nausea (usually transient), dry mouth, insomnia, sexual dysfunction, modest blood pressure (BP) increase.
Venlafaxine: Alternative serotonin-norepinephrine reuptake inhibitor (SNRI); evidence in painful polyneuropathy; stronger norepinephrine effect at higher doses (≥150 mg/day); requires cardiac monitoring at higher doses.
Topical Treatments
Topical agents allow higher local drug concentrations at the site of pain with minimal systemic absorption and side effects:
- Lidocaine 5% patch: U.S. Food and Drug Administration-approved for postherpetic neuralgia; applied to the most painful skin area for up to 12 hours/day; blocks sodium channels in peripheral nerve terminals; essentially no systemic effect; can be cut to fit; particularly useful in allodynia
- Capsaicin 8% patch: Applied in clinic under local anesthesia for 60 minutes; causes initial intense burning then prolonged desensitization of C fibers that carry the heat-sensing receptor TRPV1 (transient receptor potential vanilloid 1); duration of relief 3–6 months; requires re-application
- Capsaicin 0.025–0.1% cream (over-the-counter, OTC): Applied 3–4 times daily; requires 4–6 weeks for effect; compliance limited by initial burning
- Amitriptyline 2–5% cream: Compounded; used off-label for local neuropathic pain (postherpetic neuralgia, localized polyneuropathy); avoids the whole-body effects of a tricyclic antidepressant (TCA) taken by mouth
- Topical nonsteroidal anti-inflammatory drugs (diclofenac gel): More useful for musculoskeletal than pure neuropathic pain but can help in mixed presentations
Alpha-Lipoic Acid and Evidence
Alpha-lipoic acid (ALA) is a naturally occurring antioxidant made by the body and found in small amounts in spinach, broccoli, and red meat. It plays a role in mitochondrial energy metabolism. For neuropathic pain, it acts as:
- Potent antioxidant: Scavenges reactive oxygen species that damage peripheral nerve fibers; regenerates vitamins C and E; improves endoneurial blood flow in diabetic neuropathy
- Mitochondrial support: Restores nerve energy metabolism impaired by diabetes and other causes
Clinical evidence: alpha-lipoic acid is the most evidence-supported natural treatment for diabetic peripheral neuropathy. The landmark SYDNEY trials (intravenous alpha-lipoic acid 600 mg/day × 3 weeks) showed significant reduction in total symptom score vs. placebo. In the SYDNEY 2 trial (2006; 181 people with diabetic nerve damage in Russia and Israel), oral alpha-lipoic acid taken once a day for 5 weeks at 600 mg, 1,200 mg or 1,800 mg lowered the total symptom score (stabbing pain, burning pain, pins and needles and numbness of the feet) by 51%, 48% and 52%, against 32% with placebo. At least half of the symptom score went away in 62%, 50% and 56% of people, against 26% on placebo. Nausea, vomiting and vertigo rose with the dose, and the authors concluded that 600 mg once daily gives the best balance of benefit and side effects. Alpha-lipoic acid is approved as a drug for diabetic neuropathy in Germany. In the US it is sold as a supplement (R-lipoic acid — the more bioavailable form — or racemic R+S).
Dose: the oral trial doses were 600–1,800 mg once daily; in SYDNEY 2, 600 mg once daily worked as well as 1,200 or 1,800 mg with fewer side effects. Side effects: gastrointestinal (GI) upset, rash; the research raises a concern for people with thiamine deficiency (it can worsen the deficiency).
Other Treatment Options
- Tricyclic antidepressants (TCAs): Amitriptyline, nortriptyline — oldest medications proven for neuropathic pain; work via norepinephrine/sodium channel mechanism; very cheap; limited by anticholinergic side effects (dry mouth, constipation, urinary retention, sedation) and cardiac risk in overdose/elderly; nortriptyline has fewer side effects than amitriptyline
- Opioids: Tramadol has combined opioid + serotonin-norepinephrine reuptake inhibitor mechanism; modest NNT for neuropathic pain; other opioids are third-line due to tolerance, dependence, and modest long-term evidence
- Low-dose naltrexone: 1.5–4.5 mg at bedtime; anti-inflammatory via blockade of toll-like receptor 4 (TLR4) on microglia; evidence in fibromyalgia and small fiber neuropathy
- Sodium channel blockers: Carbamazepine/oxcarbazepine — first-line for trigeminal neuralgia specifically; blocks ectopic nerve firing
- Spinal cord stimulation (SCS): U.S. Food and Drug Administration-approved for failed back surgery syndrome and CRPS; strong evidence; reversible. In the SENZA-PDN trial (2021; 216 people in the US with painful diabetic neuropathy not helped by gabapentinoids and at least one other class of pain drug), 79% had at least half their pain relieved at 3 months with 10-kHz spinal cord stimulation added to usual care, against 5% with usual care alone. Average pain fell from 7.6 to 1.7 cm on a 10 cm scale by 6 months, and 2% of the stimulation group needed the device removed because of infection.
- Transcranial magnetic stimulation (TMS): Emerging evidence for central neuropathic pain
- Ketamine: intravenous (IV) infusions in specialized centers for refractory central and peripheral neuropathic pain
The 2025 NeuPSIG update: A review of 313 trials covering 48,789 adults made a strong recommendation for tricyclic antidepressants, alpha-2-delta ligands (gabapentin, pregabalin) and SNRIs as first-line treatments; a weak recommendation for capsaicin 8% patches, capsaicin cream and lidocaine 5% plasters as second line; and a weak recommendation for botulinum toxin A, repetitive transcranial magnetic stimulation and opioids as third line. The numbers needed to treat were 4.6 for tricyclic antidepressants, 8.9 for alpha-2-delta ligands, 7.4 for SNRIs, 5.9 for opioids, 2.7 for botulinum toxin A and 13.2 for capsaicin 8% patches. The authors describe treatment outcomes as modest, with uncertainty remaining for some treatments.
Complications
Neuropathic pain complications cascade: sleep deprivation from nocturnal pain leads to daytime fatigue and cognitive dysfunction; depression (40–65% prevalence in neuropathic pain); anxiety and catastrophizing (amplify pain perception); reduced physical activity leads to deconditioning and worsening pain; disability and unemployment; medication side effects (especially sedation with gabapentinoids and anticholinergic effects with tricyclic antidepressants); in diabetic neuropathy — loss of protective sensation leads to foot ulcers, infections, and amputations (described as largely preventable with foot care and glucose control).
Key Research Papers
- Treede RD et al., 2008 — Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. — PubMed PMID: 18003941
- Bouhassira D et al., 2004 — Development and validation of the Neuropathic Pain Symptom Inventory. Pain. — PubMed PMID: 15030944
- Bouhassira D et al., 2005 — Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. — PubMed PMID: 15733628
- Finnerup NB et al., 2015 — Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. — PubMed PMID: 25575710
- Raskin J et al., 2005 — A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. — PubMed PMID: 16266355
- Ziegler D et al., 1995 — Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. — PubMed PMID: 8786016
- Ziegler D et al., 2006 — Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. — PubMed PMID: 17065669
- Derry S et al., 2014 — Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. — PubMed PMID: 25058164
- Cruccu G et al., 2016 — EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol. — PubMed PMID: 27511815
- Moore RA et al., 2011 — Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. — PubMed PMID: 21412914
- Derry S et al., 2019 — Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. — PubMed PMID: 30673120
- Soliman N et al., 2025 — Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. — PubMed PMID: 40252663
- Tesfaye S et al., 2022 — Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet. — PubMed PMID: 36007534
- Petersen EA et al., 2021 — Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. — PubMed PMID: 33818600
PubMed Topic Searches
Connections
- Pain & Allergy
- Chronic Pain
- Complex Regional Pain Syndrome
- Migraine
- Fibromyalgia
- Trigeminal Neuralgia
- Type 2 Diabetes
- Vitamin B12
- Magnesium
- Nociceptive vs Neuropathic vs Nociplastic Pain — how to tell nerve-damage pain apart from the other two pain mechanisms, and why the label changes treatment.